Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
212 Clinical Trials near Clemmons, NC
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerDeucravacitinib for Psoriasis
Winston-Salem, North Carolina
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Non-plaque Psoriasis, Others
360 Participants Needed
Faricimab for Diabetic Macular Edema
Winston-Salem, North Carolina
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Untreated Diabetes, Active Cancer, Stroke, Others
Must Be Taking:Insulin, Anti-hyperglycemics
218 Participants Needed
Dupilumab for Asthma
Winston-Salem, North Carolina
This trial is testing dupilumab, a medication that reduces lung inflammation, in adults with moderate to severe asthma that isn't controlled by usual treatments. It aims to see if dupilumab can help improve breathing and slow down lung damage.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:COPD, Active Infection, Cancer, Others
Must Be Taking:Inhaled Corticosteroids, LABA
1324 Participants Needed
Triple Therapy for Uncontrolled Asthma
Winston-Salem, North Carolina
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Life-threatening Asthma, COPD, Others
Must Be Taking:ICS, ICS/LABA
1357 Participants Needed
AV7909 Vaccine Booster for Anthrax
Winston-Salem, North Carolina
This trial tests the AV7909 vaccine on healthy adults aged 18-65 to see if it is safe and effective. The vaccine helps the body produce antibodies that can neutralize harmful substances. The AV7909 vaccine has shown to elicit a more robust immune response in older adults.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Schizophrenia, Others
Must Not Be Taking:Herbal Medicines, Corticosteroids
220 Participants Needed
GRI-0621 for Pulmonary Fibrosis
Winston-Salem, North Carolina
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks.
Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers).
An early-stage patient variability assessment will be completed when 12 subjects have completed 2 weeks of treatment. Followed by an interim analysis performed when 24 subjects complete 6 weeks of treatment.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 85
Key Eligibility Criteria
Disqualifiers:Emphysema, Coronary Artery Disease, Others
Must Not Be Taking:CYP2C8 Inhibitors, CYP2C8 Inducers
36 Participants Needed
Lorundrostat + Dapagliflozin for Kidney Disease
Winston-Salem, North Carolina
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not Listed
60 Participants Needed
TTI-101 for Idiopathic Pulmonary Fibrosis
Winston-Salem, North Carolina
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+
Key Eligibility Criteria
Disqualifiers:Respiratory Infections, Surgery, Cardiac Disorders, Others
Must Be Taking:Nintedanib
75 Participants Needed
D-0120 + Allopurinol for Gout
Winston-Salem, North Carolina
D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cancer, Pregnancy, Breastfeeding, Others
Must Be Taking:Allopurinol
80 Participants Needed
OG-6219 for Endometriosis
Winston-Salem, North Carolina
This trial is testing a new medication called OG-6219 to see if it can help pre-menopausal women aged 18 to 49 who suffer from moderate to severe endometriosis-related pain. The medication likely works by reducing inflammation or altering hormones to relieve pain.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 49
Sex:Female
Key Eligibility Criteria
Disqualifiers:Not Listed
380 Participants Needed
Targeted Therapy for Triple Negative Breast Cancer
Winston-Salem, North Carolina
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Stage IV Disease, Active Second Malignancy, Uncontrolled Disease, Severe Allergies, Others
Must Not Be Taking:Immunosuppressants, Investigational Agents
197 Participants Needed
PXS-5505 for Myelofibrosis
Winston-Salem, North Carolina
This trial tests a new drug, PXS-5505, for safety and tolerance in patients with specific bone marrow disorders. It aims to find the best dose and see if combining it with another medication improves treatment.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:HIV, Active Hepatitis, Recent Cancer, Others
Must Be Taking:Ruxolitinib
43 Participants Needed
Atrasentan for Kidney Disease
Winston-Salem, North Carolina
This trial is testing a pill called atrasentan that may help people with certain kidney diseases by reducing harmful protein levels in their urine. It targets patients whose kidney function is getting worse despite standard treatments. The goal is to see if this medication can protect their kidneys.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other CKD, Transplant, Hypertension, Heart Failure, Malignancy, Others
Must Be Taking:RAS Inhibitors, SGLT2 Inhibitors
103 Participants Needed
Ivermectin + Digital Interaction for Rosacea
Winston-Salem, North Carolina
This trial tests if using a skin cream, online surveys, and a skin moisture measuring device can help patients with rosacea stick to their treatment and prevent their condition from getting worse.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Skin Conditions, Ivermectin Allergy
Must Be Taking:Ivermectin
30 Participants Needed
BRTX-100 for Chronic Lumbar Disc Disease
Winston-Salem, North Carolina
This is a double-blind, controlled, randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 60
Key Eligibility Criteria
Disqualifiers:Spinal Deformity, Obesity, Autoimmune, Others
Must Not Be Taking:Anticoagulants, NSAIDs, Opioids, Others
99 Participants Needed
Atezolizumab + Cobimetinib for Lung Cancer
Clemmons, North Carolina
This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving atezolizumab and cobimetinib may work better in treating patients with non-small cell lung cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Autoimmune Disease, Others
Must Not Be Taking:Immunosuppressants, CYP3A4 Inhibitors
51 Participants Needed
IMGN632 for BPDCN
Winston-Salem, North Carolina
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Disease, Veno-occlusive Disease, Others
Must Not Be Taking:Checkpoint Inhibitors
179 Participants Needed
Targeted Therapy for Cancer
Winston-Salem, North Carolina
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Illness, Cardiac Issues, Others
Must Not Be Taking:Warfarin, Protease Inhibitors
6452 Participants Needed
Muscle Fiber Fragment Treatment for Urinary Incontinence
Winston-Salem, North Carolina
This trial uses a patient's own muscle tissue to help control urine leakage by injecting it into the bladder area. It targets patients with weak bladder muscles that can't properly control urine flow, aiming to strengthen these muscles and improve urine control. Research has explored using muscle cells for reconstructing the lower urinary tract.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Hypercontractile Bladder, HIV, Diabetes, Others
Must Not Be Taking:Urination Affecting Drugs
10 Participants Needed
Camoteskimab for Eczema
Winston-Salem, North Carolina
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Skin Diseases, Severe Comorbidities, Active Infections, Others
Must Not Be Taking:Biologics, JAK Inhibitors
62 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
Itepekimab for Bronchiectasis
Winston-Salem, North Carolina
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
Study details include:
* The study duration (screening, 24-52-week treatment, 20-week safety follow-up) will be up to 47-77 weeks.
* The treatment duration will be up to 24-52 weeks.
* The follow-up duration will be 20 weeks.
* Site/phone visits are at a monthly interval.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cystic Fibrosis, Immunodeficiency, Tuberculosis, Autoimmune, Others
Must Not Be Taking:Antimicrobials, Immunosuppressants
312 Participants Needed
Zilebesiran for High Blood Pressure
Winston-Salem, North Carolina
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Secondary Hypertension, Orthostatic Hypotension, Others
Must Be Taking:Antihypertensives
375 Participants Needed
LY3972406 for Psoriasis
Winston-Salem, North Carolina
This trial is testing a new medication called LY3972406 to see if it can help adults with moderate-to-severe plaque psoriasis. The goal is to find out if it works well and is safe to use. Plaque psoriasis causes red, scaly patches on the skin, and this medication aims to reduce these symptoms.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Skin Conditions, Active Infection, Autoimmune Diseases, Others
75 Participants Needed
BMF-219 for Type 1 Diabetes
Winston-Salem, North Carolina
This trial tests BMF-219, an oral medication that blocks a protein called menin, in people with Type 1 Diabetes. The goal is to see if it can help their insulin-producing cells work better and improve how their bodies handle sugar and fats.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:MODY, T2D, Cardiovascular Disease, Others
Must Be Taking:Insulin
37 Participants Needed
CagriSema for Chronic Kidney Disease and Type 2 Diabetes in Obesity
Winston-Salem, North Carolina
This trial is testing a new medicine called CagriSema to see if it can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and who are overweight or obese. The study will compare CagriSema to two other medicines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Hereditary Kidney Diseases, Dialysis, Others
Must Be Taking:Ace Inhibitors, Arbs
618 Participants Needed
Rosnilimab for Ulcerative Colitis
Winston-Salem, North Carolina
This trial is testing a new medication called Rosnilimab to see if it can help people with moderate to severe ulcerative colitis. The study will check if the medication is safe and if it works well to reduce inflammation in the colon. Researchers want to find out if Rosnilimab can improve symptoms for those who haven't had success with other treatments.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Crohn's Disease, Fulminant Colitis, Colectomy, Others
Must Not Be Taking:Anti-TNF, Biologics, JAK Inhibitors, S1P Modulators
132 Participants Needed
Budigalimab + ABBV-382 for HIV/AIDS
Winston-Salem, North Carolina
This trial is testing two new drugs, Budigalimab and ABBV-382, to treat HIV. It involves adults with stable HIV who will pause their usual treatment. The goal is to see if these new drugs can control the virus better.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CD4+ Nadir <= 200, Others
Must Be Taking:Antiretroviral Therapy
163 Participants Needed
INS018_055 for Idiopathic Pulmonary Fibrosis
Winston-Salem, North Carolina
This trial tests a new oral medication, INS018_055, in adults with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medication is safe and well-tolerated over a few months.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Key Eligibility Criteria
Disqualifiers:Acute IPF Exacerbation, Smoking, Pregnancy, Others
Must Be Taking:Antifibrotics
40 Participants Needed
Immunotherapy for Triple-Negative Breast Cancer
Winston-Salem, North Carolina
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, CNS Metastases, Autoimmune Disease, Cardiovascular Disease, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids
83 Participants Needed
Vixarelimab for Pulmonary Fibrosis
Winston-Salem, North Carolina
This trial is testing vixarelimab, a medication that may help improve lung function, in people with IPF and SSc-ILD. It works by reducing inflammation and scarring in the lungs to help with breathing.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Lung Transplant, Malignancy, Immunodeficiency, Others
Must Be Taking:Pirfenidone, Nintedanib, Tocilizumab
320 Participants Needed
Know someone looking for new options?
Spread the word